Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cristian Massacesi

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Palliative Medicine|October 25, 2006
Sustained release octreotide may have a role in the treatment of malignant bowel obstructionCristian Massacesi, Giordano Galeazzi
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 16, 2005
Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinomaCristian Massacesi, Luciano Burattini, Fabiana Marcucci, et al.
Annals of the New York Academy of Sciences|April 5, 2013
Challenges in the clinical development of PI3K inhibitorsCristian Massacesi, Emmanuelle di Tomaso, Nathalie Fretault, et al.
Advances in Therapy|April 21, 2021
Curative-Intent Treatment with Durvalumab in Early-Stage CancersGiovanni Melillo, Vikram Chand, Alejandro Yovine, et al.
Oncology|November 29, 2002
Desmoplastic small round cell tumour: a description of two cases and review of the literaturePaolo Lippe, Rossana Berardi, Claudia Cappelletti, et al.
American Journal of Clinical Oncology|April 11, 2002
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimensCristian Massacesi, Barbara Pistilli, Michele Valeri, et al.
Anticancer Research|August 10, 2002
Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patientsPaolo Lippe, Rosa R Silva, Luciano Giuliodori, et al.
Breast Cancer Research and Treatment|November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerGuy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Medical Oncology (Northwood, London, England)|March 23, 2004
Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii studyDaniele Santini, Cristian Massacesi, Rolando Maria D'Angelillo, et al.
Cancer|February 4, 2006
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapyCristian Massacesi, Salvatore Terrazzino, Fabiana Marcucci, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Palliative Medicine|October 25, 2006
Sustained release octreotide may have a role in the treatment of malignant bowel obstructionCristian Massacesi, Giordano Galeazzi
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 16, 2005
Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinomaCristian Massacesi, Luciano Burattini, Fabiana Marcucci, et al.
Annals of the New York Academy of Sciences|April 5, 2013
Challenges in the clinical development of PI3K inhibitorsCristian Massacesi, Emmanuelle di Tomaso, Nathalie Fretault, et al.
Advances in Therapy|April 21, 2021
Curative-Intent Treatment with Durvalumab in Early-Stage CancersGiovanni Melillo, Vikram Chand, Alejandro Yovine, et al.
Oncology|November 29, 2002
Desmoplastic small round cell tumour: a description of two cases and review of the literaturePaolo Lippe, Rossana Berardi, Claudia Cappelletti, et al.
American Journal of Clinical Oncology|April 11, 2002
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimensCristian Massacesi, Barbara Pistilli, Michele Valeri, et al.
Anticancer Research|August 10, 2002
Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patientsPaolo Lippe, Rosa R Silva, Luciano Giuliodori, et al.
Breast Cancer Research and Treatment|November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerGuy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Medical Oncology (Northwood, London, England)|March 23, 2004
Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii studyDaniele Santini, Cristian Massacesi, Rolando Maria D'Angelillo, et al.
Cancer|February 4, 2006
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapyCristian Massacesi, Salvatore Terrazzino, Fabiana Marcucci, et al.
Pageof 3